NEW YORK, Dec. 16, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced two new members to its Board of Governors: Gavin Cook, Executive Director of Global Alzheimer's ...
The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, ...
On Thursday, April 7, the Centers for Medicare and Medicaid (CMS) formalized its plan to cover the anti-amyloid drug Aduhelm only for patients enrolled in clinical trials. However, in response to ...
Findings point to continued momentum toward combination therapies that target the full pathobiology of the disease NEW YORK, May 14, 2026 /PRNewswire/ -- Today, Biogen announced topline results from ...
Data show that the anti-amyloid is modestly effective in reducing cognitive decline, underscoring the need to develop additional drugs that target other pathways guided by the biology of aging NEW ...
NEW YORK, March 17, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional ...
SACRAMENTO, Calif.--(BUSINESS WIRE)--NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, ...
NEW YORK, NY (July 8, 2020) - The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals have granted Eugenia Trushina, Ph.D., of Mayo Clinic Rochester ...
San Francisco, CA (November 30, 2022) – The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results